ABSTRACT AJCP /ORIGINAL ARTICLE. Downloaded from by guest on 07 January 2019
|
|
- Lester Black
- 5 years ago
- Views:
Transcription
1 Correlation of Circulating Complement-Fixing Donor-Specific Antibodies Identified by the C1q Assay and Presence of C4d in Endomyocardial Biopsy Specimens Renee Frank, MD, 1 Priti Lal, MD, 1 Jane Kearns, CHS, 1 Maria R. Molina, MSN, CRNP, 2 Joyce W. Wald, DO, 2 Lee R. Goldberg, MD, MPH, 2 and Malek Kamoun, MD, PhD 1 From the 1 Department of Pathology and Laboratory Medicine, and 2 Heart Failure and Cardiac Transplant Program, Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA Key Words: Endomyocardial biopsy; C4d; C1q assay; Donor-specific antibody Am J Clin Pathol January 2016;145:62-68 DOI: /AJCP/AQV016 ABSTRACT Objectives: Donor-specific antibodies (DSAs) are associated with increased cardiac graft loss. We applied a C1q solidphase assay in parallel with the standard immunoglobulin G (IgG) single antigen bead (SAB) assay to examine the correlation of circulating complement-fixing donor-specific antibodies and the presence of C4d in endomyocardial biopsy (EMB) specimens. Methods: We retrospectively studied the relationship of C1qþ DSAs and C4d immunofluorescence (IF) in 49 EMB specimens from 44 heart transplant recipients who had concurrent EMB, C4d IF, and DSA measurements. We applied a C1q SAB in parallel with the standard IgG SAB assay to examine the DSA profiles in heart transplant patients posttransplant. Results: A better concordance is observed between C1qþ DSAs with C4d IFþ compared with IgG DSAs with C4d IF þ (40% vs 24%, P ¼.02). However, the correlation of C1q DSAs with C4d IF is not statistically significant (P ¼.24). Importantly, C1qþ DSAs were observed in 16 of 17 cases with C4d IFþ; 24 cases had circulating C1qþ DSAs without detectable C4d staining, suggesting that that the presence of C1qþ DSAs may precede the detection of C4d deposition in EMB specimens and/or the development of antibody-mediated rejection. Conclusions: In this cohort of 44 patients, no significant correlation was observed between circulating C1q DSAs and C4d IF in EMB specimens. Additional studies are needed to further evaluate the association of C1q DSAs with EMB specimens and C4d staining. Donor-specific antibodies (DSAs) are associated with increased cardiac allograft injury and loss, including vascular injury and graft dysfunction. Detection of antibody-mediated rejection (AMR) relies in part on graft dysfunction, endomyocardial biopsy (EMB) histopathologic criteria, and circulating DSAs. 1,2 DSAs can be against anti class I human leukocyte antigen (HLA), anti class II HLA, or non anti-hla antibodies. 3 Since Patel and Terasaki 4 demonstrated a significant correlation between a positive crossmatch and hyperacute and accelerated acute grafts dysfunction in kidney transplants using a complement-dependent cytotoxicity (CDC) assay in 1969, there has been no highly sensitive andspecificassaypredictive of clinical outcomes in transplantation patients. The currently available assays for detection of DSAs uses either CDC, or flow cytometry or Luminex (Luminex Corporation, Austin TX) technology using beads coated with single HLA antigens. While these assays are highly sensitive, they fail to differentiate antibodies that fix complement and cause graft injury or dysfunction from antibodies that do not cause graft injury or dysfunction. In the end, it is the pathogenicity, or ability of the antibody to fix complement, that is most pertinent to the acute and chronic effects of DSAs and ultimately clinical outcome. 5-8 Detection of antibodies capable of binding complement, specifically antibodies binding the first component of the classic pathway, C1q, gives the earliest indication of the potential for complement-mediated injury. 9,10 A C1q single antigen bead (SAB) assay to detect complement-fixing HLA antibodies has recently been developed. 9,11 This assay is highly sensitive and specific for distinguishing subsets of immunoglobulin G (IgG) antibodies that can fix complement and assess risk of early clinical AMR in cardiac 62 Am J Clin Pathol 2016;145:62-68 American Society for Clinical Pathology, All rights reserved. For permissions, please journals.permissions@oup.com
2 allografts. 12,13 A strong correlation between preformed complement-fixing DSAs detected by a C1q SAB, positive CDC crossmatch, and early clinical AMR has also been shown. 12,13 Interestingly, in the kidney transplantation literature, complement-fixing DSAs detected by a C1q SAB fixation and C4d deposition in kidney transplant biopsy specimens do not appear to be directly correlated. 14 In the cardiac transplant literature, studies have evaluated early clinical AMR with C4d staining of EMB specimens and complement-fixing DSAs detected by a C1q SAB assay; however, to our knowledge, there are no systematic studies evaluating DSAs detected by a C1q SAB with C4d staining and other parameters, including demographics and comorbidity factors. 15,16 We applied a C1q SAB in parallel with the standard IgG SAB to examine the correlation of circulating complement-fixing donor-specific antibodies and presence of C4d in EMB specimens. Materials and Methods Patient Population In this retrospective analysis, we studied the relationship of complement-fixing DSAs and C4d immunofluorescence (IF) in 40 EMB specimens from 38 cases of previously selected heart transplant recipients. 17 Heart transplant patients ( ) with concurrent endomyocardial biopsy, immunofluorescence for C4d, and DSA measurements were initially selected. Thirty-eight patients had stored serum samples available for this analysis. Clinical data gathered included patient demographics, presence and HLA class specificity of DSAs, ejection fraction (EF), nonimmunologic comorbidities, and cause of death. Nonimmunologic comorbidities gathered from the electronic medical record included presence or absence of hypertension, diabetes mellitus, cytomegalovirus (CMV) viremia, obesity, and hyperlipidemia CMV viremia was defined as symptomatic patients with a quantitative CMV viral load of more than 5,000 copies/ml who were treated with intravenous (IV) ganciclovir. Allograft dysfunction was defined as a precipitous decline in EF by at least 10% or an EF 35% or less, detected by transthoracic echocardiogram or transesophageal echocardiogram. To be included in the cohort, the measurement of EF was done within 61 month of the EMB. Cardiovascular mortality was defined by death due to acute AMR, acute myocardial infarction, and progressive allograft dysfunction and heart failure. For the purposes of this study, patients who died of noncardiac causes were censored from the graft failure analysis. Official cause of death was obtained from our electronic medical record systems, which were recorded directly from the patient death certificate and autopsy report when applicable. The maintenance immunosuppression protocols, including a calcineurin inhibitor, antimetabolite, or a cell cycle inhibitor, have been described in our previous study. 17 At our institution, all patients are on maintenance immunosuppression protocols, including a calcineurin inhibitor, antimetabolite, or a cell cycle inhibitor. The target tacrolimus level is 10 to 15 lg/l at 0 to 6 months, 10 to 12 lg/l at 6 to 12 months, 8 to 10 lg/l at 12 to 24 months, and 5 to 8 lg/l at more than 24 months. The target cyclosporine level is 200 to 300 ng/ml at 1 to 6 months, 150 to 200 ng/ ml at 6 to 12 months, 120 to 175 ng/ml at 12 to 24 months, and 80 to 100 ng/ml at more than 24 months. All patients who exhibit acute cellular rejection (ACR) grade 2R are treated with IV solumedrol, 1 g, for 3 days if the patient is status posttransplant less than 6 months, or prednisone, 100 mg, for 5 days if the patient is status posttransplant more than 6 months. If the patient is exhibiting ACR grade 2R or 3R with hemodynamic compromise and a decrease in EF of more than 10%, then the patient will also be treated with received rabbit anti thymocyte globulin (thymoglobulin). There was no difference in treatment since all treatments were similar for each patient, with the exception of plasmapheresis and photopheresis. Access to patient medical record information and review of archived myocardial biopsy tissue was granted approval by the Hospital of the University of Pennsylvania Institutional Review Board. Endomyocardial IF IF for C4d is performed on one to three pieces of fresh tissue submitted by the clinical team in addition to tissue for routine H&E evaluation. C4d IF staining is not performed in our institution within the first 2 weeks of transplantation. In general, fresh-frozen tissue was analyzed by indirect IF microscopy technique by using antibodies directed against C4d primary affinity-purified monoclonal antibody (dilution, 1:50; 30-minute incubation at room temperature; Sigma Aldrich, St Louis, MO). The fresh-frozen tissues were cut at 3 to 4 lm thickness and mounted on single-ring positively charged slides (Fisher, Pittsburgh, PA). Staining was performed according to standard procedures. Indirect IF microscopy was performed on a Nikon OPTISHOT with a Nikon Coolscan V ED camera (Nikon, Melville, NY) using Image Pro Plus (Media Cybernetics, Rockville, MD). Interstitial capillary C4d staining was semiquantitatively graded on a scale of 0 to 3þ for intensity, and a percentage of interstitial capillary staining over the entire parenchyma was assigned. Any EMB specimen exhibiting at least 2þ C4d staining over 50% of the interstitial capillaries was considered significant or positive for C4d deposition, an example of which is shown as Image 1. In this study, AMR was defined as clinical evidence of graft dysfunction, along with positive DSA and IF C4d (as defined above). C4d evaluation is performed at the request of the clinical team in (1) patients with clinical evidence of graft dysfunction (new American Society for Clinical Pathology Am J Clin Pathol 2016;145:
3 Frank et al /DSAS BYC1Q ASSAY WITH C4D INEMB SPECIMENS heart failure symptoms, new S3 murmur, increased jugular venous distention, and a decrease in EF of >10%), (2) patients who exhibit high percent reactive antibody, and (3) all patients with ACR of International Society for Heart and Lung Transplantation grade 3R. Most currently, AMR has been proposed to be a diagnosis rendered by pathologists, without the requirements of clinical dysfunction or positive DSAs, which was required in the past. 3,23,24 It must be emphasized that the pathologic AMR (pamr) grading system represents an initial guideline with the intention of accumulating data, validation, and patient treatment regimens. Furthermore, the recognition and diagnosis of AMR by histopathology, even among experienced transplant pathologists, is challenging. A number of studies have highlighted the problems of key morphologic criteria for the purposes of AMR screening. 25,26 The threshold for therapeutic intervention in patients with AMR remains unknown, particularly in the setting of asymptomatic AMR. For these reasons, we have not used the pamr grade to evaluate the utility of the C1q assay. HLA Typing and Evaluation of Anti-HLA Antibodies HLA typing was performed on all donors and recipients using DNA-based methods. Initial HLA typing included HLA-A, B, C, DRB1, DRB3/4/5, and DQB1. For recipients with antibodies against HLA-DQA, DP, or allele specific antibodies, additional typing of these loci for donors and recipients was also performed on a subset of these patients. Identification of anti-hla antibodies was performed using Image 1 Endomyocardial biopsy specimen exhibiting at least 2þ C4d staining over 50% of the interstitial capillaries, considered positive for C4d deposition. A, Unremarkable myocardium (H&E, 5). B, Myocardium with diffuse endothelial cell proliferation (arrows) and interstitial myxoid change (arrowheads) (H&E, 5). C, C4d immunofluorescence in interstitial capillaries. 64 Am J Clin Pathol 2016;145:62-68 American Society for Clinical Pathology 64
4 solid-phase class I and class II assays, which included flow cytometry bead and/or Luminex bead assays. At least two antibody solid-phase testing methods were used, one of which was a mixed-bead class I and class II assay or a class I and class II phenotype assay. HLA specificities were confirmed by single-antigen bead assays (One Lambda, Canoga Park, CA). Evaluation of complement-binding anti-hla antibodies was detected by using C1q single antigen bead assays (One Lambda). For sensitized patients, antibody testing included HLA-A, B, C, DRB1, DRB3/4/5, DQA1, DQB1, and DPB1 specificities. A retrospective or prospective flow cytometric crossmatch was performed on all patients. The strength of antibody determined using solid-phase assays was correlated with the crossmatch test results. Donor-specific anti-hla antibodies were considered positive if the median fluorescence intensity assessed by Luminex single antigen bead assays was greater than 1,000 for IgG and higher than 400 for the C1q assays. Statistical Analysis Statistical analysis was performed using Fisher s exact t test and a paired samples t test. Statistical significance was defined as P <.05 (MedCalc, version (MedCalc Software, Ostend, Belgium)). Results Patient Characteristics Upon review of our pathology archives between 2005 and 2011, a total of 109 patients had concurrent EMB, DSA evaluation, and C4d IF. 17 Of these 109 patients, 44 had stored serum samples for C1q SAB analysis. The current cohort comprises 49 allografts from 44 patients, including 11 women and 33 men. Patient demographics and characteristics are shown in Table 1. Four patients received a second cardiac transplant that was included in the study group. Of our patient cohort, four were treated with photopheresis and five were treated with a combination of plasmapheresis (courses of four to six exchanges), IV immunoglobulin, rituximab, and cytoxan. Histopathology We analyzed a total of 49 EMB and concurrent IF studies from 49 cardiac grafts in 44 patients who had pre- and posttransplant DSA measurements. Mild and moderate acute cellular rejection was seen in 32 and 12 grafts, respectively. There were no EMB specimens with severe acute cellular rejection in this cohort. As shown in Table 1, nonimmunologic comorbidities of the C1q DSA and non-c1q DSA patient groups are similar. The distribution of total IgG DSAs and Table 1 Clinical Information for Patients With C1q Donor-Specific Antibodies and Those Without C1q Donor-Specific Antibodies With Nonimmunologic Comorbidities of Patients With and Without DSAs a C1q DSAs Characteristic Positive (n ¼ 40) Negative (n ¼ 9) Sex Male 31 6 Female 9 3 Age at time of biopsy, mean 48 (21-78) 43 (22-63) (range), y Pretransplant DSAs 5 3 Concurrent episode of ACR 36 8 Etiology of heart failure Ischemic CM 10 3 Dilated CM 12 1 Hypertrophic CM 2 0 Congenital CM 1 0 Restrictive CM 1 0 Nonischemic CM NOS 14 5 Nonimmunologic comorbidities CMV viremia 7 1 Hyperlipidemia 40 8 Obesity (BMI >30 kg/m 2 ) 6 1 Diabetes mellitus 24 6 Hypertension 37 9 ACR, acute cellular rejection; BMI, body mass index; CM, cardiomyopathy; CMV, cytomegalovirus; DSAs, donor-specific antibodies; NOS, not otherwise specified. a Values are presented as numbers unless otherwise indicated. C1qþ DSAs is shown in Figure 1 ; 84% (36/43) of patients who had IgG DSAs had C1qþ complement-fixing DSAs in this selected cohort of patients. Importantly, C1qþ DSAs were observed in 16 of 17 cases with C4d IFþ; 24 cases had circulating C1qþ DSAs without detectable C4d staining Table 2. However, the correlation of C1q DSAs with C4d IF is not statistically significant (P ¼.24). EMB Characteristics and Graft Dysfunction EMB IF results were compared with corresponding graft EFs. Of the 49 biopsies, 28 (70%) EMBs were performed during a clinically significant decline in EF as defined above. Twenty-three (82%) of the 28 EMB specimens evaluated during an episode of graft dysfunction correlated with positive C1q DSAs. As shown in Table 3,in patients with positive C1q DSAs (n ¼ 23), positive C4d staining on the EMB specimen was observed in 13 (56%). In addition, in patients who were tested negative for C1q DSAs, positive C4d staining on the EMB specimen was observed in only one (20%). Graft Failure In this study group of a total of 44 patients with 49 grafts evaluated, 18 patients died or underwent a heart retransplant. Two patients were not included in the graft failure analysis American Society for Clinical Pathology Am J Clin Pathol 2016;145:
5 Frank et al /DSAS BYC1Q ASSAY WITH C4D INEMB SPECIMENS since one patient was lost to follow-up and one did not meet cardiac mortality criteria (died secondary to acute myeloid leukemia). After these two exclusions, 47 allografts were evaluated for graft failure. As shown in Table 4, overall, 38% (18/47) cardiac allografts failed. Graft failure occurred in 14 (37%) of 38 patients who tested positive for C1q DSAs and in four (44%) of nine patients who tested negative for C1q DSAs; three of these four patients developed IgG DSAs. The mean time to graft failure was 56 months and 59 months for grafts with and without C1qþ DSAs, respectively. Of the 28 allografts that survived, 24 (86%) tested positive for C1q DSAs. Similarly, 83% (15/18) of allografts that failed tested positive for C1q DSAs. No. of Cardiac Allografts C1q+ C1q No DSA (n = 6) DSA to HLA Class I (n = 5) DSA to HLA Class II (n = 19) Table 2 C4d Immunofluorescence With and Without C1q Donor- Specific Antibodies a C1q DSAs, No. (%) Characteristic Positive (n ¼ 40) Negative (n ¼ 9) Total No. C4d positive 16 (40) 1 (11) 16 C4d negative 24 (60) 8 (89) 32 Total 40 (100) 9 (100) 49 DSAs, donor-specific antibodies. a The correlation of C1q DSAs with C4d immunofluorescence is not statistically significant (P ¼.24). Table 3 Endomyocardial Biopsy During an Episode of Allograft Dysfunction With Corresponding C4d Immunofluorescence Staining (P ¼.619) C1q DSAs No C4d, No. (%) C4d >50%, No. (%) Positive (n ¼ 23) 13 (56) 10 (44) Negative (n ¼ 5) 4 (80) 1 (20) DSA to Both HLA Class I and II (n = 19) Figure 1 Donor-specific antibodies by human leukocyte antigen (HLA) class as related to C1q positivity. Discussion In this report, we present a single-institution study of a subset of 44 patients who underwent cardiac transplants and had comprehensive clinical, pathologic, and immunologic data to study the relationship of these parameters with cardiac allograft transplantation outcomes. Our data suggest no significant correlation between circulating complement-fixing DSAs detected by C1q SAB and C4d IF in EMB specimens. A better concordance is observed between C1qþ DSAs with C4d IF þ compared with total IgG DSAs with C4d IF þ (40% vs 24%, P ¼.02). Patients with concurrent data for graft dysfunction, EMB, IF for C4d, and C1q DSA were analyzed. Nonimmunologic comorbidities were also evaluated to overcome possible confounding factors, and were similar in patients who had circulating C1qþ DSAs and those who remained negative for C1q DSAs (Table 1). However, the correlation of C1q DSAs with C4d IF was not statistically significant (P ¼.24). Importantly, C1qþ DSAswereobservedin16of17caseswithC4dIFþ; 24 cases had circulating C1qþ DSAs without detectable C4d staining (Table 2), suggesting that the presence of C1qþ DSAs may precede the detection of C4d deposition in EMB specimens and/or the development of AMR. In this cohort of 38 patients, no significant correlation was observed between circulating C1q DSAs and C4d IF in EMB specimens. In patients with graft dysfunction, 82% had circulating C1q DSAs. There was no significant correlation observed between circulating C1q DSAs and graft failure; this lack of correlation may in part be due to a patient selection bias since our cohort was focused on patients who had a graft dysfunction, EMB, and IF C4d staining. The clinical utility of novel assays detecting complement binding anti-hla antibodies was recently reported in heart transplantation. 12,15 However, the role of complement-fixing Table 4 Cardiac Allograft Failure With Corresponding C1q DSA Status and C4d Immunofluorescence Staining (P ¼.716) C1q DSAs Graft Failure, No. (%) Time to Graft Failure, Mean (Range), mo Negative C4d, No./ Total No. (%) Positive C4d, No./ Total No. (%) IgG DSAs, No./ Total No. (%) Positive (n ¼ 38) a 14 (37) 56 (9-162) 9/14 (64) 5/14 (36) 14/14 (100) Negative (n ¼ 9) 4 (44) 59 (17-139) 4/4 (100) 0 3/4 (75) DSAs, donor-specific antibodies; IgG, immunoglobulin G. a Two patients censored from graft failure analysis: one patient died of acute myeloid leukemia, and the second patient was lost to follow-up. 66 Am J Clin Pathol 2016;145:62-68 American Society for Clinical Pathology 66
6 vs non complement-fixing DSAs and its correlation with C4d IF staining had not yet been elucidated. All DSAs are not equal in terms of detriment to allograft function. 27 The ability to activate the complement cascade appears to be a critical factor in differentiating clinically relevant and nonrelevant DSAs. 12 A positive C1q DSA with a negative C4d staining in EMB specimens could be due to a number of factors, including low sensitivity of IF staining, low sensitivity of the threshold used for a positive read on IF, or lack of C3d testing in our cohort. It should also be noted that a patient could have positive C4d staining without circulating DSAs secondary to non-hla antiallograft antibodies or due to complement fixation secondary to infections or other types of injuries. 28 In this cohort of 44 patients, no significant correlation was observed between circulating C1q DSAs and C4d IF in EMB specimens. Prospective studies are needed to further evaluate the association of C1q DSAs with EMB and IF C4d staining, as well as with long-term outcomes in heart transplant recipients. Because our study is limited to a small cohort, additional studies of the impact of treatment strategies of AMR with circulating C1qþ DSAs are necessary to transform the diagnostic data into an actionable treatment plan that improves long-term heart transplant outcomes. Corresponding author: Renee Frank, MD, University of Pennsylvania, 3400 Spruce St, 6th Floor, Founders Building, Philadelphia, PA 19104; renee.frank@uphs.upenn.edu. We thank Insuk Choe, JD, for help in compiling and in the critical evaluation of HLA data. We appreciate the assistance of Lynita Thomas and Christopher Mignogna with the IF processing protocols. These data were presented in part at the American Society for Histocompatibility and Immunogenetics, 39th Annual Meeting, Chicago, IL, November 17-21, References 1. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30: Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24: Berry GJ, Angelini A, Burke MM, et al. The ISHLT working formulation for pathologic diagnosis of antibody-mediated rejection in heart transplantation: evolution and current status ( ). J Heart Lung Transplant. 2011;30: Kfoury AG, Stehlik J, Renlund DG, et al. Impact of repetitive episodes of antibody-mediated or cellular rejection on cardiovascular mortality in cardiac transplant recipients: defining rejection patterns. J Heart Lung Transplant. 2006;25: Bohmig GA, Exner M, Watschinger B, et al. C4d deposits in renal allografts are associated with inferior graft outcome. Transplant Proc. 2001;33: Shahzad K, Aziz QA, Leva JP, et al. New-onset graft dysfunction after heart transplantation-incidence and mechanismrelated outcomes. J Heart Lung Transplant. 2011;30: Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol. 2005;5: Tan CD, Sokos GG, Pidwell DJ, et al. Correlation of donorspecific antibodies, complement and its regulators with graft dysfunction in cardiac antibody-mediated rejection. Am J Transplant. 2009;9: Herskowitz A, Soule LM, Ueda K, et al. Arteriolar vasculitis on endomyocardial biopsy: a histologic predictor of poor outcome in cyclosporine-treated heart transplant recipients. J Heart Transplant. 1987;6: Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibodymediated rejection. J Heart Lung Transplant. 2009;28: Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant. 2004;4: Baldwin WM, Kasper EK III, et al. Beyond C4d: other complement-related diagnostic approaches to antibody-mediated rejection. Am J Transplant. 2004;4: Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy J Heart Lung Transplant. 2010;29: Yabu JM, Higgins JP, Chen G, et al. C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation. 2011;91: Chin C, Chen G, Sequeria F, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011;30: Zeevi A, Lunz J, Feingold B, et al. Persistent strong anti- HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013;32: Frank R, Molina MR, Wald JW, et al. Correlation of circulating donor-specific anti-hla antibodies and presence of C4d in endomyocardial biopsy with heart allograft outcomes: a single-center, retrospective study. J Heart Lung Transplant. 2013;32: Braga JR, Santos IS, McDonald M, et al. Factors associated with the development of cardiac allograft vasculopathy a systematic review of observational studies. Clin Transplant. 2012;26:E111-E Chen W, Thoburn CJ, Miura Y, et al. Autoimmune-mediated vasculopathy. Clin Immunol. 2001;100: de Denus S, Al-Jazairi A, Loh E, et al. Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients. Ann Pharmacother. 2004;38: Kahn J, Rehak P, Schweiger M, et al. The impact of overweight on the development of diabetes after heart transplantation. Clin Transplant. 2006;20: American Society for Clinical Pathology Am J Clin Pathol 2016;145:
7 Frank et al /DSAS BYC1Q ASSAY WITH C4D INEMB SPECIMENS 22. McDonald K, Rector TS, Braulin EA, et al. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64: Berry GJ, Burke MM, Andersen C, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. JHeart Lung Transplant. 2013;32: Reed EF, Demetris AJ, Hammond E, et al. Acute antibodymediated rejection of cardiac transplants. J Heart Lung Transplant. 2006;25: Fedrigo M, Gambino A, Benazzi E, et al. Role of morphologic parameters on endomyocardial biopsy to detect sub-clinical antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30: Hammond ME, Stehlik J, Snow G, et al. Utility of histologic parameters in screening for antibody-mediated rejection of the cardiac allograft: a study of 3,170 biopsies. J Heart Lung Transplant. 2005;24: Stoica SC, Cafferty F, Pauriah M, et al. The cumulative effect of acute rejection on development of cardiac allograft vasculopathy. J Heart Lung Transplant. 2006;25: Amico P, Honger G, Bielmann D, et al. Incidence and prediction of early antibody-mediated rejection due to nonhuman leukocyte antigen-antibodies. Transplantation. 2008;85: Am J Clin Pathol 2016;145:62-68 American Society for Clinical Pathology 68
Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection
http://www.jhltonline.org Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection Marny Fedrigo, MD, PhD, a Giuseppe Feltrin, MD, PhD, a Francesca
More information3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial
Prevention of Complement Activation and Antibody Development: Results from the Duet Trial Jignesh Patel MD PhD FACC FRCP Medical Director, Heart Transplant Cedars-Sinai Heart Institute Disclosures Name:
More informationNo evidence of C4d association with AMR However, C3d and AMR correlated well
C4d positivity Poor prognostic factor Reversal to C4d negativity did not change prognosis, with current therapy Prognostic factor for CAV Variable time line for CAV/death No correlation with cellular rejection
More informationAntibody Mediated Rejection (AMR) in Heart Transplantation Session
Page 1 Antibody Mediated Rejection (AMR) in Heart Transplantation Session Dear Colleagues: The Heart session at Banff this year will be solely focused on AMR and besides the fact that many of us attending
More informationHLA and Non-HLA Antibodies in Transplantation and their Management
HLA and Non-HLA Antibodies in Transplantation and their Management Luca Dello Strologo October 29 th, 2016 Hystory I 1960 donor specific antibodies (DSA): first suggestion for a possible role in deteriorating
More information2017 BANFF-SCT Joint Scientific Meeting. BARCELONA March 2017
2017 BANFF-SCT Joint Scientific Meeting BARCELONA 27-31 March 2017 Adriana Zeevi PhD (D) ABHI Professor of Pathology, Surgery and Immunology Director of Histocompatibility Laboratory University of Pittsburgh
More informationAntibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients
Antibody Mediated Rejection (AMR) in LUNG TRANSPLANT Recipients Lorriana Leard, MD UCSF Transplant Pulmonologist Associate Professor of Clinical Medicine Vice Chief of Clinical Activities Pulmonary, Critical
More informationThe new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials
The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials Carmen Lefaucheur 1 2 Banff 2015: Integration of HLA-Ab for improving
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated
More informationPost-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies
Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies Lorita M Rebellato, Ph.D., D (ABHI) Associate Professor Department of Pathology The Brody School of Medicine at ECU Scientific
More informationEvaluation of Two New Antibody Detection Techniques in Kidney Transplantation. Doctoral Thesis. Dr. Petra Gombos
Evaluation of Two New Antibody Detection Techniques in Kidney Transplantation Doctoral Thesis Dr. Petra Gombos Semmelweis University Doctoral School of Pathology Supervisor: Dr. Róbert Langer, Ph.D. Consultant:
More informationAntibody-Mediated Rejection in the Lung Allograft. Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305
Antibody-Mediated Rejection in the Lung Allograft Gerald J Berry, MD Dept of Pathology Stanford University Stanford, CA 94305 Gerald J Berry, MD Professor of Pathology Stanford University, Stanford, CA
More informationAntibody Mediated Rejection in Heart Transplantation
Antibody Mediated Rejection in Heart Transplantation 2012 Teresa De Marco, MD, FACC Professor of Medicine & Surgery Director Heart Failure and Pulmonary Hypertension Program Medical Director, Heart Transplantation
More informationResearch Article The Natural History of Biopsy-Negative Rejection after Heart Transplantation
Transplantation Volume 2013, Article ID 236720, 6 pages http://dx.doi.org/10.1155/2013/236720 Research Article The Natural History of Biopsy-Negative Rejection after Heart Transplantation Zhaoyi Tang,
More informationMary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT. 4th April 2014
Solid Organ Transplantation How the Lab Contributes to Improved Patient Outcomes Mary Keogan, on Mary behalf Keogan of all in NHISSOT On behalf of all in NHISSOT 4th April 2014 Solid Organ Transplantation
More informationChronic injury to the microcirculation in EMB
Chronic injury to the microcirculation in EMB Dylan V Miller MD M Patricia Revelo MD Disclosures Miller: None Revelo: None Goals & Objectives Characterize the tissue-level pathologic changes occurring
More informationAntihuman leukocyte antigen (HLA) antibodies can be
Antihuman Leukocyte Antigen Specific Antibody Strength Determined by Complement-Dependent or Solid-Phase Assays Can Predict Positive Donor-Specific Crossmatches Ibrahim Batal, MD; Adriana Zeevi, PhD; John
More informationMarta Farrero Torres₁, Marcelo Pando₂, Dolly Tyan₂, Hannah Valantine₃, Spenser Smith₃, Kiran Khush₃
Development of HLA donor specific antibodies after heart transplantation: importance of a new method to detect the first component of the complement cascade Marta Farrero Torres₁, Marcelo Pando₂, Dolly
More informationReview of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology
Review of Rituximab and renal transplantation Dr.E Nemati Professor of Nephrology Introductio n Rituximab is a chimeric anti-cd20 monoclonal antibody. The CD20 antigen is a transmembrane nonglycosylated
More informationSolid Organ Transplant
Solid Organ Transplant Lee R. Goldberg, MD, MPH, FACC Associate Professor of Medicine Medical Director, Heart Failure and CardiacTransplant Program University of Pennsylvania Disclosures Thoratec Consulting
More informationIs it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines
Is it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines Dr Martin Howell. Laboratory Director. Department of H&I, NHS Blood and Transplant,
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding
More informationPosttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients
Trends in Transplant. 2014;8:3-9 Gregor Bartel, Georg A. Böhmig: Alloantibodies and Graft Function Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients Gregor Bartel
More informationTransplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab
ORIGINAL ARTICLE Advance Access publication 1 February 2010 Transplantation in highly sensitised patients treated with intravenous immunoglobulin and Rituximab Ana Carina Ferreira 1, Sandra Brum 1, Vasco
More informationRenal Pathology- Transplantation. Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic
Renal Pathology- Transplantation Eva Honsova Institute for Clinical and Experimental Medicine Prague, Czech Republic eva.honsova@ikem.cz Kidney has a limited number of tissue reactions by which the kidney
More informationEndothelitis in cardiac allograft biopsy specimens: Possible relationship to antibody-mediated rejection
http://www.jhltonline.org ORIGINAL CLINICAL SCIENCE Endothelitis in cardiac allograft biopsy specimens: Possible relationship to antibody-mediated rejection Fabio Tavora, MD, a Raghava Munivenkatappa,
More informationPredictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
Pediatr Transplantation 2013: 17: 436 440 2013 John Wiley & Sons A/S. Pediatric Transplantation DOI: 10.1111/petr.12095 Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients
More informationWhy so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation
Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation Stephen J Tomlanovich MD Objectives of this Talk Define the sensitized patient Describe the scope of the problem for a
More information6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?
6/19/212 KPD Webinar Series: Part 3 Demystifying the OPTN Kidney Paired Donation Pilot Program Unacceptable HLA antigens: The key to finding a compatible donor for your patient M. Sue Leffell, Ph.D. J.
More informationDE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY
2016 DE-MYSTIFYING THE BLACK BOX OF TRANSPLANT IMMUNOLOGY James H Lan, MD, FRCP(C), D(ABHI) Clinical Assistant Professor, University of British Columbia Nephrology & Kidney Transplantation, Vancouver General
More informationVirtual Crossmatch in Kidney Transplantation
Virtual Crossmatch in Kidney Transplantation Shiva Samavat Associate Professor of Nephrology Labbafinejad Hospital SBMU 2018.11.21 All transplant candidates are screened to determine the degree of humoral
More informationTransplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation
AACC Professional Course BETH ISRAEL DEACONESS MEDICAL CENTER HARVARD MEDICAL SCHOOL Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation J. Ryan
More informationC4d Fixing, Luminex Binding Antibodies A New Tool for Prediction of Graft Failure After Heart Transplantation
American Journal of Transplantation 27; 7: 289 2815 Blackwell Munksgaard Brief Communication C 27 The Authors Journal compilation C 27 The American Society of Transplantation and the American Society of
More informationEfficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function
ArtIcle Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function Guodong Chen, 1 Jingli Gu, 2 Jiang Qiu, 1 Changxi
More informationSerum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant
SDC, Patients and Methods Complement-dependent lymphocytotoxic crossmatch test () Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant donor-specific CXM was
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationManagement of Rejection
Management of Rejection I have no disclosures Disclosures (relevant or otherwise) Deborah B Adey, MD Professor of Medicine University of California, San Francisco Kidney and Pancreas Transplant Center
More information3/6/2017. Treatment of Detected Antibodies. I have financial relationship(s) with: Thoratec/St. Jude/Abbott Consultant CareDx Consultant/Speaker
Treatment of Detected Antibodies Sean Pinney, MD Director, Advanced Heart Failure & Transplantation Mount Sinai Hospital New York, NY Sean Pinney, MD Associate Professor of Medicine Icahn School of Medicine
More informationClinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly Sensitized Renal Transplanted Patients
BioMed Research International Volume 2013, Article ID 738404, 5 pages http://dx.doi.org/10.1155/2013/738404 Clinical Study Different Impact of Pretransplant Anti-HLA Antibodies Detected by Luminex in Highly
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationTreatment of Chronic Antibody Mediated Rejection
Treatment of Chronic Antibody Mediated Rejection Robert A. Montgomery MD, DPhil Professor of Surgery Director of the NYU Langone Transplant Institute Disclosures: Served on Advisory Boards for Genentech
More informationResearch Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting Antibody-Mediated Rejection
Clinical and Developmental Immunology Volume 2013, Article ID 460316, 6 pages http://dx.doi.org/10.1155/2013/460316 Research Article The Diagnostic Value of Transcription Factors T-bet/GATA3 Ratio in Predicting
More informationBackground & objectives
Indian J Med Res 145, February 2017, pp 222-228 DOI: 10.4103/ijmr.IJMR_222_16 Quick Response Code: Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with
More informationSolid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions
Solid Organ Transplantation 1 Chapter 55. Solid Organ Transplant, Self-Assessment Questions Questions 1 to 9 are related to the following case: A 38-year-old white man is scheduled to receive a living-unrelated
More informationPre-transplant donor specific antibody and its clinical significance in kidney transplantation
Original article Pre-transplant donor specific antibody and its clinical significance in kidney transplantation Duangtawan Thammanichanond, 1 Atiporn Ingsathit, 2,3 Tasanee Mongkolsuk, 1 Sasivimol Rattanasiri,
More informationKathryn J. Lindley, 1, 2 Ashwin K. Ravichandran, 1, 2 Joel Schilling, 1, 2, 3 and Susan M. Joseph 1, Introduction
Case Reports in Cardiology Volume 2012, Article ID 639284, 4 pages doi:10.1155/2012/639284 Case Report Antibody-Mediated Rejection of the Heart in the Setting of Autoimmune Demyelinating Polyneuropathy:
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationIMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar
IMMUNOBIOLOGY OF TRANSPLANTATION Wasim Dar Immunobiology of Transplantation Overview Transplantation: A complex immunologic process Contributions Innate Immunity Adaptive immunity T Cells B Cells HLA Consequences
More informationInnovative Application of Immunologic Principles in Heart Transplantation
The Ochsner Journal 10:231 235, 2010 f Academic Division of Ochsner Clinic Foundation Innovative Application of Immunologic Principles in Heart Transplantation Stacy A. Mandras, MD,* Joaquin Crespo, MD,{
More informationHeart Transplant: State of the Art. Dr Nick Banner
Heart Transplant: State of the Art Dr Nick Banner Heart Transplantation What is achieved Current challenges Donor scarcity More complex recipients Long-term limitations Non-specific Pharmacological Immunosuppression
More informationPUO in the Immunocompromised Host: CMV and beyond
PUO in the Immunocompromised Host: CMV and beyond PUO in the immunocompromised host: role of viral infections Nature of host defect T cell defects Underlying disease Treatment Nature of clinical presentation
More informationRetransplant and Medical Therapy for Cardiac Allograft Vasculopathy: International Society for Heart and Lung Transplantation Registry Analysis
American Journal of Transplantation 2016; 16: 301 309 Wiley Periodicals Inc. Brief Communication C Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons
More informationEculizumab chez les receveurs de greffe rénal à haut risque immunologique. Mark D. Stegall Mayo Clinic, Rochester, MN
Eculizumab chez les receveurs de greffe rénal à haut risque immunologique Mark D. Stegall Mayo Clinic, Rochester, MN Disclosure. Dr Mark Stegall. Institution : Mayo Clinic, Rochester. Research contracts
More informationKidney paired donation in the presence of donor-specific antibodies
http://www.kidney-international.org & 2013 International Society of Nephrology clinical investigation Kidney paired donation in the presence of donor-specific antibodies Jeremy M. Blumberg 1, Hans A. Gritsch
More informationPeritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance
ORIGINAL ARTICLE Port J Nephrol Hypert 2008; 22(1): 37-42 Peritubular capillaries C4d deposits in renal allograft biopsies and anti HLA I/II alloantibodies screening Incidence and clinical importance Helena
More informationCopyright information:
Posttransplant reduction in preexisting donor-specific antibody levels after belataceptversus cyclosporine-based immunosuppression: Post hoc analyses of BENEFIT and BENEFIT-EXT Robert A Bray, Emory University
More informationObjectives 3/6/2017. Impact of Non-HLA Antibodies in Lung Transplantation
Impact of Non-HLA Antibodies in Lung Transplantation Nancy L. Reinsmoen, Ph.D., D(ABHI) Director, HLA and Immunogenetics Laboratory (Retired) Cedars Sinai Medical Center Los Angeles, CA Nancy L. Reinsmoen,
More informationPulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017
Pulmonary AMR Therapeutic Options & Strategies: The Old and the New Ramsey Hachem, MD March 28, 2017 Disclosures Ramsey Hachem I have no financial relations with any relevant commercial interests I will
More informationQuantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b
Quantifying HLA-specific antibodies in patients undergoing desensitization Andrea Zachary a and Nancy L. Reinsmoen b a John Hopkins University, Immunogenetics Laboratory, Baltimore, Maryland and b Cedars-Sinai
More informationDesensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver
Desensitization in Kidney Transplant James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver Organ Shortage Currently there are >90,000 patients on the kidney
More informationDonor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative Renal Transplants
Available online at www.annclinlabsci.org 330 Annals of Clinical & Laboratory Science, vol. 40, no. 4, 2010 Donor-Specific HLA Class I and CREG Antibodies in Complement-Dependent Cytotoxicity-Negative
More informationAPHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS
APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS GOW AREPALLY, MD MEDICAL DIRECTOR DUKE THERAPEUTIC APHERESIS SERVICE ASSOCIATE PROFESSOR, MEDICINE AMERICAN SOCIETY FOR APHERESIS MAY 25 TH 2013 OVERVIEW
More informationBasel - 6 September J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva
Basel - 6 eptember 2012 J.-M. Tiercy National Reference Laboratory for Histocompatibility (LNRH) University Hospital Geneva Outline the HLA system is (a) complex anti-hla immunisation and alloreactivity
More informationTransfusion support in Transplantation
Transfusion support in Transplantation Patricia Campbell University of Alberta Hospitals University of Alberta Objectives UofA transplant programs What we do and why? HLA and ABO incompatible transplants
More informationThe multidisciplinary approach to AMR in lung transplantation: Reaching a consensus. Deborah Jo Levine Professor of Medicine University of Texas
The multidisciplinary approach to AMR in lung transplantation: Reaching a consensus Deborah Jo Levine Professor of Medicine University of Texas Disclosures I have no financial relations with any relevant
More informationReview Article Clinical Relevance of HLA Antibody Monitoring after Kidney Transplantation
Hindawi Publishing Corporation Journal of Immunology Research Volume 2014, Article ID 845040, 5 pages http://dx.doi.org/10.1155/2014/845040 Review Article Clinical Relevance of HLA Antibody Monitoring
More informationHLA Antibody Complement Based Assays. Howard M. Gebel, PhD, D(ABHI) Robert A. Bray, PhD, D(ABHI) Emory University Hospital Atlanta, GA
HLA Antibody Complement Based Assays Howard M. Gebel, PhD, D(ABHI) Robert A. Bray, PhD, D(ABHI) Emory University Hospital Atlanta, GA Disclosure Neither presenter has any financial relationships related
More informationHistocompatibility Evaluations for HSCT at JHMI. M. Sue Leffell, PhD. Professor of Medicine Laboratory Director
Histocompatibility Evaluations for HSCT at JHMI M. Sue Leffell, PhD Professor of Medicine Laboratory Director JHMI Patient Population Adults Peds NMDP data >20,000 HSCT JHMI HSCT Protocols Bone marrow
More informationRevisiting Traditional Risk Factors for Rejection and Graft Loss After Kidney Transplantation
American Journal of Transplantation 2011; 11: 2132 2143 Wiley Periodicals Inc. C 2011 The Authors Journal compilation C 2011 The American Society of Transplantation and the American Society of Transplant
More informationPopulations Interventions Comparators Outcomes Individuals: With heart transplant
Protocol Laboratory Tests for Heart Transplant Rejection (20168) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/18 Preauthorization No Review Dates: 05/13, 05/14, 05/15, 05/16, 05/17 This
More informationCHAPTER 3 LABORATORY PROCEDURES
CHAPTER 3 LABORATORY PROCEDURES CHAPTER 3 LABORATORY PROCEDURES 3.1 HLA TYPING Molecular HLA typing will be performed for all donor cord blood units and patients in the three reference laboratories identified
More informationPredicting Kidney Graft Failure by HLA Antibodies: a Prospective Trial
American Journal of Transplantation 2004; 4: 438 443 Blackwell Munksgaard Copyright C Blackwell Munksgaard 2004 doi: 10.1111/j.1600-6143.2004.00360.x Predicting Kidney Graft Failure by HLA Antibodies:
More informationInterstitial Inflammation
Interstitial Inflammation Currently considered to be T cell-mediated process Plasma cell rich acute rejection often associated with AMR Preliminary data suggests that interstitial follicular helper T cells
More informationACCME/Disclosure. Case #1. Case History. Dr. Bracamonte has nothing to disclose
Case #1 ACCME/Disclosure Dr. Erika Bracamonte Associate Professor of Pathology University of Arizona, College of Medicine Banner University Medical Center, Tucson Dr. Bracamonte has nothing to disclose
More informationRenal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches
Transplant International ISSN 0934-0874 ORIGINAL ARTICLE Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement-dependent cytotoxicity) crossmatches Kyu Ha Huh,
More informationDonor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients
Donor-derived Cell-free DNA Improves DSA-informed Diagnosis of ABMR in Kidney Transplant Patients Stanley C. Jordan, MD Director, Division of Nephrology Medical Director, Kidney Transplant Program Medical
More informationTransplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes
Transplant Success in Sensitized Patients Receiving a Standardized Desensitization Therapy: 3 Year Outcomes INTRODUCTION In patients awaiting a transplant, having antibodies reactive to HLA antigens present
More informationFigure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.
New Insights into Antibody Mediated Graft Injury after Pediatric Liver Transplantation S.V. McDiarmid MD Professor of Pediatrics and Surgery David Geffen School of Medicine University of California, Los
More informationKidney Summary. Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA
Kidney Summary Mark Haas Cedars-Sinai Medical Center Los Angeles, California, USA Key Issues to Address re: the Classification 1. Incorporation of i-ifta + tubulitis into the TCMR classification - Defining
More informationRENAL EVENING SPECIALTY CONFERENCE
RENAL EVENING SPECIALTY CONFERENCE Harsharan K. Singh, MD The University of North Carolina at Chapel Hill Disclosure of Relevant Financial Relationships No conflicts of interest to disclose. CLINICAL HISTORY
More informationTransplantation. Immunology Unit College of Medicine King Saud University
Transplantation Immunology Unit College of Medicine King Saud University Objectives To understand the diversity among human leukocyte antigens (HLA) or major histocompatibility complex (MHC) To know the
More informationDonor-Specific HLA Alloantibodies: Long-Term Impact on Cardiac Allograft Vasculopathy and Mortality After Heart Transplant
Donor-Specific HLA Alloantibodies: Long-Term Impact on Cardiac Allograft Vasculopathy and Mortality After Heart Transplant Ingo Kaczmarek, 1 Marcus-André Deutsch, 1 Teresa Kauke, 2 Andres Beiras-Fernandez,
More informationThe diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss
http://www.kidney-international.org 2015 International Society of Nephrology see commentary on page 218 The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk
More informationDr. Yi-chi M. Kong August 8, 2001 Benjamini. Ch. 19, Pgs Page 1 of 10 TRANSPLANTATION
Benjamini. Ch. 19, Pgs 379-399 Page 1 of 10 TRANSPLANTATION I. KINDS OF GRAFTS II. RELATIONSHIPS BETWEEN DONOR AND RECIPIENT Benjamini. Ch. 19, Pgs 379-399 Page 2 of 10 II.GRAFT REJECTION IS IMMUNOLOGIC
More informationSymposium. Post-operative Management Of Pediatric Heart Transplantation : A Brief Review
DOI-10.21304/2018.0503.00394 Symposium Post-operative Management Of Pediatric Heart Transplantation : A Brief Review Balakrishnan KR*, Suresh KG**, Muralikrishna T***, Suresh Kumar R **** *Director, Cardiac
More informationThis study is currently recruiting participants.
A Two Part, Phase 1/2, Safety, PK and PD Study of TOL101, an Anti-TCR Monoclonal Antibody for Prophylaxis of Acute Organ Rejection in Patients Receiving Renal Transplantation This study is currently recruiting
More informationClass II Alloantibody and Mortality in Simultaneous Liver-Kidney Transplantation
Wiley Periodicals Inc. C Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons Class II Alloantibody and Mortality in Simultaneous Liver-Kidney Transplantation
More informationResearch Article The Induction of IgM and IgG Antibodies against HLA or MICA after Lung Transplantation
Pulmonary Medicine Volume 2, Article ID 43269, 9 pages doi:.55/2/43269 Research Article The Induction of IgM and IgG Antibodies against HLA or MICA after Lung Transplantation Annelieke W. M. Paantjens,
More informationClinical history. 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Cardiac catheterization: no CAD
CASE 8 Clinical history 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Concentric hypertrophy Hypokinesis of LV-Inf Cardiac catheterization: no CAD Technique
More informationMeeting Report. Introduction
American Journal of Transplantation 2017; 17: 42 53 Wiley Periodicals Inc. Meeting Report 2016 The Authors. American Journal of Transplantation published by Wiley Periodicals, Inc. on behalf of American
More informationStrategies for Desensitization
Strategies for Desensitization Olwyn Johnston MB, MRCPI, MD, MHSc BC Nephrology Day October 8 th 2010 Pre-transplant crossmatch (CMX) with donor lymphocytes has been standard of practice Positive CDC CXM
More informationUtility of protocol kidney biopsies for de novo donor- specific antibodies
Received: 6 June 2017 Revised: 24 July 2017 Accepted: 29 July 2017 DOI: 10.1111/ajt.14466 BRIEF COMMUNICATION Utility of protocol kidney biopsies for de novo donor- specific antibodies Sandesh Parajuli
More informationResearch Article Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect on Long-Term Graft Survival
Clinical and Developmental Immunology Volume 2013, Article ID 828201, 5 pages http://dx.doi.org/10.1155/2013/828201 Research Article Anti-HLA and Anti-MICA Antibodies in Liver Transplant Recipients: Effect
More informationMedicine OBSERVATIONAL STUDY
Medicine OBSERVATIONAL STUDY Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients Hyeyoung Lee, MD,
More informationOriginal Article Diagnostic Immunology INTRODUCTION
Original Article Diagnostic Immunology Ann Lab Med 2012;32:139-144 ISSN 2234-3806 eissn 2234-3814 Clinical Relevance of Pretransplant HLA Class II Donor-specific Antibodies in Renal Transplantation Patients
More informationTRANSPLANT IMMUNOLOGY. Shiv Pillai Ragon Institute of MGH, MIT and Harvard
TRANSPLANT IMMUNOLOGY Shiv Pillai Ragon Institute of MGH, MIT and Harvard Outline MHC / HLA Direct vs indirect allorecognition Alloreactive cells: where do they come from? Rejection and Immunosuppression
More information23/10/2017. Panel Reactive Antibodies and Crossmatch by Flow Cytometry. Antibodies against. Renal transplantation. Antibody mediated rejection (AMR)
Renal transplantation Panel Reactive Antibodies and Crossmatch by Flow Cytometry Katherina Psarra Immunology Histocompatibility Dept Evangelismos Hospital Athens, Greece In spite of the enormous progress
More informationTrends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant and relationship to BK virus infection
2565 Nephrol Dial Transplant (2012) 27: 2565 2570 doi: 10.1093/ndt/gfr675 Advance Access publication 13 December 2011 Trends in immune function assay (ImmuKnow; Cylexä) results in the first year post-transplant
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationIncidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review
Incidence of Rejection in Renal Transplant Surgery in the LVHN Population Leading to Graft Failure: 6 Year Review Jessica Ludolph 1 Lynsey Biondi, MD 1,2 and Michael Moritz, MD 1,2 1 Department of Surgery,
More information